icad inc. Cost of Revenue

Cost of Revenue of ICAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).

Highlights and Quick Summary

  • Cost of Revenue for the quarter ending March 30, 2021 was $2.41 Million (a -20.59% decrease compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue increased by 91.42%
  • Annual Cost of Revenue for 2020 was $8.54 Million (a 15.62% increase from previous year)
  • Annual Cost of Revenue for 2019 was $7.39 Million (a 13.75% increase from previous year)
  • Annual Cost of Revenue for 2018 was $6.5 Million (a -37.41% decrease from previous year)
  • Twelve month Cost of Revenue ending March 30, 2021 was $8.86 Million (a 3.71% increase compared to previous quarter)
  • Twelve month trailing Cost of Revenue increased by 20.2% year-over-year
Trailing Cost of Revenue for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
$8.86 Million $8.54 Million $7.72 Million $7.37 Million
Visit stockrow.com/ICAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of icad inc.

Most recent Cost of Revenueof ICAD including historical data for past 10 years.

Interactive Chart of Cost of Revenue of icad inc.

icad inc. Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $2.41
2020 $3.04 $2.16 $1.26 $2.09 $8.54
2019 $2.22 $1.8 $1.6 $1.49 $7.39
2018 $1.54 $1.45 $1.38 $1.82 $6.5
2017 $3.56 $2.36 $1.91 $2.1 $10.38
2016 $2.4 $1.9 $1.67 $1.85 $8.94
2015 $2.32 $2.76 $3.27 $3.86 $12.2
2014 $3.87 $3.41 $2.84 $2.59 $12.7
2013 $2.85 $2.36 $2.49 $2.28 $9.98
2012 $2.27 $2.3 $1.76 $1.92 $8.24
2011 $2.11 $2.16 $2.14 $2.21 $8.63
2010 $1.32 $1.13 $4.88

Business Profile of icad inc.

Sector: Healthcare
Industry: Health Information Services
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.